This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: ASCO

Moving on. Pablo writes, "Congrats for your superb job with the ASCO blogs. Since I'm not cool enough to know how to use Twitter, I'm sending you a very old fashioned email. Now that the ASCO conference and post sell-off craziness is over (at least I hope so because I was one of the schmucks who bought high and kept holding the bags) would you be kind enough to give your target range for some of the stocks I hold: Ziopharm Oncology, Oxigene (OXGN), Celldex Therapeutics (CLDX - Get Report), Sunesis Pharmaceuticals, Aeterna Zentaris (AEZN) and Hana BioSciences (TICKER) (HNAB.OB)."

That's quite a speculative list of biotech stocks, Pablo. I hope these holdings make up a small percentage of your overall investment portfolio. Don't risk money you absolutely need in small-cap biotech stocks -- that would be my over arching advice to you.

I like Ziopharm the most from your list. I think Celldex had a fine ASCO in terms of phase II data on its brain tumor "vaccine" but the company is in a bit of dead zone while it waits for partner Pfizer (PFE) to design and start the phase III study. The rest of Celldex's drug pipeline is totally overlooked and probably deserves more credit.

Sunesis has two issues to deal with -- raising money to move its lead drug voreloxin into a phase III AML study and then getting the study started. Aeterna didn't make an impact clinically at ASCO; future value depends on the outcome of phase III studies underway for its lead drug perifosine, outlicensed to Keryx Pharmaceuticals (KERX).

Oxigene? Meh. I didn't follow Hana at ASCO.

@lomu_j tweets, "Surprisingly, Delcath hasn't raised cash and they probably need it more."

@johnwelshphd adds, "Delcath and Celldex are getting shorted at will because they did not do their shelf before ASCO and got greedy after big runs."

Both guys make good points. Delcath has less than $30 million in the bank and will raise money, either through stock sales or a partnership. [The bet is on the former, which is another reason why the stock sold off after ASCO.]

Ziopharm raised about $33 million at $5 a share right before ASCO. At the time, investors were emailing me a bit miffed and puzzled at the company's decision sell stock before ASCO. Today, the offering looks smart.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $1.24 -0.40%
BMY $67.94 -0.21%
CELG $112.56 0.19%
CLDX $17.93 0.22%
DCTH $0.48 6.67%


Chart of I:DJI
DOW 17,787.97 -25.42 -0.14%
S&P 500 2,088.72 -0.15 -0.01%
NASDAQ 5,121.3950 +5.2520 0.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs